Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer
Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

Read more on News-Medical-Net

Tags: , , , , , , , , , , ,

This entry was posted on Tuesday, June 8th, 2010 at 5:37 pm and is filed under Thyroid Disease. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

        
Business Solutions           Employee Time Clock           Business Coach           Miami Roofer           HP Support           IP Address Lookup           Coralgables Roofing Company           Speed Test           PMP Training           Body Bands           Pinecrest Roofing Company          Get Life Insurance          Miami Metal Roofer         

Make taxes & bookkeeping easier with Shoeboxed.com I made $447.50 selling this laptop on eBay



Leave a Reply